APONTIS PHARMA Revenue and Competitors
Estimated Revenue & Valuation
- APONTIS PHARMA's estimated annual revenue is currently $20.7M per year.
- APONTIS PHARMA's estimated revenue per employee is $201,000
Employee Data
- APONTIS PHARMA has 103 Employees.
- APONTIS PHARMA grew their employee count by -1% last year.
APONTIS PHARMA's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Tax /Accounting /Supply Chain | Reveal Email/Phone |
2 | Product Manager | Reveal Email/Phone |
3 | Netzwerk Managerin | Reveal Email/Phone |
4 | Medical Manager | Reveal Email/Phone |
5 | Key Account Payer Access Manager | Reveal Email/Phone |
6 | Regionaler Vertriebsleiter | Reveal Email/Phone |
7 | Pharmareferentin | Reveal Email/Phone |
8 | Assistenz Marketing | Reveal Email/Phone |
9 | Wissenschaftlicher Außendienst APONTIS-PHARMA | Reveal Email/Phone |
10 | Praxis- & Pharmaberater | Reveal Email/Phone |
APONTIS PHARMA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is APONTIS PHARMA?
APONTIS PHARMA is a pharmaceutical company focused on the commercialization of innovative pharmaceutical products to General Practitioners (GPs) and Internal Medicine Specialists in Germany. 
APONTIS PHARMA emerged in 2018 as a spin-off from a global pharmaceutical company UCB. APONTIS PHARMA builds on its long-standing UCB's and Schwarz Pharma's heritage.
keywords:N/AN/A
Total Funding
103
Number of Employees
$20.7M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
APONTIS PHARMA News
DGAP-News: APONTIS PHARMA: START-Studie in wissenschaftlicher Publikation veröffentlicht - Kostenred.. Finanzen CH
APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pill therapy Yahoo Finance
Paragon-backed Apontis Pharma announces IPO intention Unquote
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23.1M | 149 | 24% | N/A |
#2 | $59.4M | 200 | 0% | N/A |
#3 | $59M | 219 | -1% | N/A |
#4 | $3.5M | 369 | 6% | N/A |
#5 | $3.5M | 432 | 6% | N/A |